



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Axumin

Procedural steps taken and scientific information after the authorisation*

*Due to Agency`s update of its procedure management systems, an additional document, capturing the historical lifecycle may be available in the 'Assessment history' section. For the complete lifecycle procedures, please also refer to **EPAR - Procedural steps taken and scientific information after authorisation (archive)**.

Application number	Scope	Opinion/ Notification ¹ issued on	Commission Decision Issued ² / amended on	Product Information affected ³	Summary
Variation type IB /	This was an application for a group of	03/10/2024		SmPC,	

¹ Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

² A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

³ SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).



EMA/VR/0000227755

variations.

B.II.e.7 Change in supplier of packaging components or devices (when mentioned in the dossier) - B.II.e.7.b Replacement or addition of a supplier - Accepted

B.II.b.3 Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - B.II.b.3.z Other changes - Accepted

B.II.b.2 Change to importer, batch release arrangements and quality control testing of the finished product - B.II.b.2.a Replacement or addition of a site where batch control/testing takes place - Accepted

B.II.b.2.c Replacement or addition of a manufacturer responsible for importation and/or batch release - B.II.b.2.c.2 Including batch control/testing - Accepted

B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.a Secondary packaging site - Accepted

B.II.b.1 Replacement or addition of a manufacturing site for part or all of the

Labelling and
PL

	<p>manufacturing process of the finished product - B.II.b.1.f Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for sterile medicinal products (including those that are aseptically manufactured) excluding biological/ immunological medicinal products - Accepted</p>				
<p>Variation type IA / EMA/VR/0000224587</p>	<p>This was an application for a group of variations.</p> <p>B.II.b.2 Change to importer, batch release arrangements and quality control testing of the finished product - B.II.b.2.a Replacement or addition of a site where batch control/testing takes place - Accepted</p> <p>B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted</p> <p>B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.d Deletion of a non-significant specification parameter</p>	<p>27/08/2024</p>	<p>N/A</p>		

	(e.g. deletion of an obsolete parameter) - Refused				
--	---	--	--	--	--